PKS Advisory Services LLC Invests $56,000 in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

PKS Advisory Services LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,500 shares of the company’s stock, valued at approximately $56,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of CRVS. Nwam LLC bought a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $53,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Corvus Pharmaceuticals in the fourth quarter worth $73,000. XTX Topco Ltd acquired a new position in Corvus Pharmaceuticals during the third quarter worth $74,000. Virtu Financial LLC bought a new position in Corvus Pharmaceuticals in the third quarter valued at $83,000. Finally, Three Bridge Wealth Advisors LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at $120,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on CRVS shares. Oppenheimer restated an “outperform” rating and set a $15.00 price objective (up from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.63.

Corvus Pharmaceuticals Trading Down 14.8 %

NASDAQ CRVS opened at $3.35 on Thursday. The firm has a market capitalization of $215.26 million, a P/E ratio of -3.60 and a beta of 0.91. The firm’s fifty day moving average price is $4.67 and its two-hundred day moving average price is $6.08. Corvus Pharmaceuticals, Inc. has a 1 year low of $1.30 and a 1 year high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.06). On average, research analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.